Neurogene Inc. (NASDAQ:NGNE)
| Market Cap | $350.02M+8.4% |
| Revenue (ttm) | $0 |
| Net Income | -$119.18M-40.0% |
| EPS | -$5.57-25.7% |
| Shares Out | 15.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 178,269 |
| Open | $22.27 |
| Previous Close | $22.93 |
| Day's Range | $22.00 - $22.90 |
| 52-Week Range | $15.93 - $43.66 |
| Beta | 2.09 |
| Analysts | Buy |
| Price Target | $72.00(+225.06%) |
| Earnings Date | Mar 23, 2027 |
About NGNE
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating NGNE in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 23, 2027Earnings report
$NGNE stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in NGNE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NGNE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NGNE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New NGNE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NGNE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NGNE
| VTIVanguard Morningstar Total Stock Market ETF | $11.31M |
| IWMiShares Russell 2000 ETF | $9.41M |
| XBIState Street SPDR S&P Biotech ETF | $6.28M |
| VXFVanguard Extended Market ETF | $4.87M |
| IWNiShares Russell 2000 Value ETF | $3.37M |
| IBBiShares Biotechnology ETF | $2.74M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from NGNE’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst expectations for significant upside rally combined with Q3 earnings reporting suggest constructive market positioning.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BBC | Virtus Biotech Clinical Trials ETF | 0.64% |
| IBRN | iShares Neuroscience and Healthcare ETF | 0.59% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.31% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.31% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.26% |
| HELX | Franklin Genomic Advancements ETF | 0.16% |
| IWC | iShares Micro-Cap ETF | 0.10% |
| PJSM | PGIM Jennison Small-Mid Cap Core Equity ETF | 0.08% |
| TSEE | T. Rowe Price Small Cap ETF | 0.07% |
| XBI | State Street SPDR S&P Biotech ETF | 0.07% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.05% |
| FESM | Fidelity Enhanced Small Cap ETF | 0.04% |
Weight is the stock’s share of each fund’s holdings.
